Skip to Content
Merck
  • Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism.

Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism.

Cell chemical biology (2019-11-18)
Evan R Abt, Ethan W Rosser, Matthew A Durst, Vincent Lok, Soumya Poddar, Thuc M Le, Arthur Cho, Woosuk Kim, Liu Wei, Janet Song, Joseph R Capri, Shili Xu, Nanping Wu, Roger Slavik, Michael E Jung, Robert Damoiseaux, Johannes Czernin, Timothy R Donahue, Arnon Lavie, Caius G Radu
ABSTRACT

Biosynthesis of the pyrimidine nucleotide uridine monophosphate (UMP) is essential for cell proliferation and is achieved by the activity of convergent de novo and salvage metabolic pathways. Here we report the development and application of a cell-based metabolic modifier screening platform that leverages the redundancy in pyrimidine metabolism for the discovery of selective UMP biosynthesis modulators. In evaluating a library of protein kinase inhibitors, we identified multiple compounds that possess nucleotide metabolism modifying activity. The JNK inhibitor JNK-IN-8 was found to potently inhibit nucleoside transport and engage ENT1. The PDK1 inhibitor OSU-03012 (also known as AR-12) and the RAF inhibitor TAK-632 were shown to inhibit the therapeutically relevant de novo pathway enzyme DHODH and their affinities were unambiguously confirmed through in vitro assays and co-crystallization with human DHODH.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Dipyridamole, ≥98% (HPLC)
Sigma-Aldrich
Uridine, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Coenzyme Q10, ≥98% (HPLC)
Sigma-Aldrich
Pyrimidine, ≥98.0%
Sigma-Aldrich
4-(Trifluoromethoxy)benzamidoxime, 97%
Sigma-Aldrich
Potassium hexacyanoferrate(III), ACS reagent, ≥99.0%